Global FluoroSpot Market, By Product (Assay Kits, Analyzers, Ancillary Products), Application (Diagnostic Applications, Research Applications, Cancer Research, Drug Discovery, and Disease Diagnosis), End User (Hospitals and Clinical Laboratories, Biopharmaceutical Companies, Research Institute) – Industry Trends and Forecast to 2029
FluoroSpot Market Analysis and Size
According to the Globocan 2020, there were roughly 9,958,133 cancer-related deaths worldwide and an estimated 19,292,789 new cancer cases that were identified. Additionally, the International Agency for Research on Cancer (IARC) predicts that by 2040, there will be 16.3 million cancer-related deaths globally and 27.5 million new instances of cancer. FluoroSpot demand is anticipated to be driven by the rising number of cancer cases.
Data Bridge Market Research analyses that the fluoroSpot market which was USD 214.56 million in 2021, would rocket up to USD 738.10 million by 2029, and is expected to undergo a CAGR of 16.70% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
FluoroSpot Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Assay Kits, Analyzers, Ancillary Products), Application (Diagnostic Applications, Research Applications, Cancer Research, Drug Discovery, and Disease Diagnosis), End User (Hospitals and Clinical Laboratories, Biopharmaceutical Companies, Research Institute)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Thermo Fisher Scientific Inc. (U.S.), BD (U.S.), Bio-Rad Laboratories, Inc. (U.S.), bioMérieux (France), Merck KGaA (Germany), RayBiotech Life Inc. (U.S.), R&D Systems, Inc. (U.S.), AESKU.GROUP GmbH & Co. KG (Germany), Eurofins Scientific (Luxembourg), Biogenuix (India), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), Danaher (U.S.), Sysmex Corporation (Japan), PerkinElmer Inc. (U.S.), Agilent Technologies Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Fluorospot assays are especially well suited for screenings because of their great sensitivity and simplicity of use. Other benefits include the assay's ability to be used with fresh and cryopreserved samples, making it particularly appealing for several sites taking part in the same study. The dual-color fluoroSpot assay is a modification of the ELISPOT assay and developed for the simultaneous detection of two cytokines released by a single T cell.
FluoroSpot Market Dynamics
Drivers
- Increase in diagnostic technologies
According to the World Health Organization, over 354 million individuals worldwide are estimated to have hepatitis B or C infections in 2020. The need for a diagnosis arise due to the rising occurrence of infectious diseases. The expansion of the market is related to the rising use of cutting-edge diagnostic technologies for illness screening, such as enzyme linked immunosorbent assay.
- Rising chronic diseases
According to the World Health Organization's December 2020 report, the major chronic diseases currently account for over 60% of all fatalities and 43% of the burden of disease globally. By 2020, it is anticipated that their share of global morbidity and mortality will reach 60% and 73 percent, respectively. Additionally, chronic diseases account for 79 percent of mortality in underdeveloped nations. Additionally, market expansion is anticipated to be fuelled by technological advancements in assay kits and analyzers for fluoroSpot.
- Rising healthcare expenditure
According to the Center for Disease Control and Prevention 2021, the leading causes of mortality and disability in the United States are chronic diseases like heart disease, cancer, and diabetes. Additionally, they are primarily responsible for the USD3.8 trillion in annual healthcare expenditures in the US. As a result of increasing healthcare costs and the incidence of chronic diseases, the market is expected to rise throughout the forecast period.
Opportunities
- Increase in the number of research and development activities
The market's growth is fuelled by rising number of patients with infectious diseases around the world, the proliferation of innovative and novel products, and the use of advanced technology for multiple diagnosis are expected to boost the growth of the fluoroSpot market.
On the other hand, throughout the forecast period, the market will expand due to the launch of numerous medications and other discoveries that will further boost potential of the market.
Restraints/Challenges
On the other hand, the easy availability of alternative methods will obstruct the market's growth rate.
This fluoroSpot market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the fluoroSpot market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on FluoroSpot Market
The COVID-19 pandemic had a substantial influence on the fluoroSpot market in addition to having an impact on the world's healthcare systems. In COVID-19, there appears to be a correlation between antibody titers and T-cell responsiveness, according to an article from Medtech that was released in 2020. Three individuals (C4, C5, and C7) with the lowest antibody response in COVID-19 patients had the largest T cell response as the highest number of IFN-/IL-2 secreting cells in a FluoroSpot experiment. As a result, in COVID-19 patients, the flurospot are employed to assess the T- and B-cell immunity specific to SARS-CoV-2. The unexpected outbreak of COVID-19 and its global spread are among the key causes of this surge in the growth of the markets for FluoroSpot.
Global FluoroSpot Market Scope
The fluoroSpot market is segmented on the basis of product, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Assay Kits
- Analyzers
- Ancillary Products
Application
- Diagnostic Applications
- Research Applications
- Cancer Research
- Drug Discovery
- Disease Diagnosis
End User
- Hospitals and Clinical Laboratories
- Biopharmaceutical Companies
- Research Institute
FluoroSpot Market Regional Analysis/Insights
The fluoroSpot market is analysed and market size insights and trends are provided by product, application and end user as referenced above.
The countries covered in the fluoroSpot market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the fluoroSpot market owing to the emergence in the abundance of businesses, developed healthcare foundation, and the extent of communicable disorders and the improvement of several innovative commodities.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the rising number of patient population along with developing of infrastructure and adoption of diagnostic tools.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and FluoroSpot Market Share Analysis
The fluoroSpot market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to fluoroSpot market.
Some of the major players operating in the fluoroSpot market are:
- Thermo Fisher Scientific Inc. (U.S.)
- BD (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- bioMérieux (France)
- Merck KGaA (Germany)
- RayBiotech Life Inc. (U.S.)
- R&D Systems, Inc. (U.S.)
- AESKU.GROUP GmbH & Co. KG (Germany)
- Eurofins Scientific (Luxembourg)
- Biogenuix (India)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Abbott (U.S.)
- Danaher (U.S.)
- Sysmex Corporation (Japan)
- PerkinElmer Inc. (U.S.)
- Agilent Technologies Inc. (U.S.)
SKU-